A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2018
At a glance
- Drugs Natalizumab (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- Acronyms OPUS
- Sponsors Biogen
- 01 Aug 2018 Planned End Date changed from 22 Apr 2022 to 17 Jul 2020.
- 24 Oct 2017 Status changed from not yet recruiting to recruiting in Oct 2017, according to a Biogen media release.
- 18 Sep 2017 New trial record